Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System
This study offers an enhanced comprehension of the potential AEs that could be induced by teplizumab, thereby furnishing invaluable insights for its clinical application.
Authors
- W. J. Zheng (ORCID: https://orcid.org/0009-0002-1240-6393)
- Jianjun Ji (ORCID: https://orcid.org/0009-0007-5356-6832)
- Changjiang Wang (ORCID: https://orcid.org/0000-0002-0425-7976)
- Yu Wang (ORCID: https://orcid.org/0000-0002-5651-4751)
- Yi Shen (ORCID: https://orcid.org/0009-0006-0062-5344)
- Pengfei Du (ORCID: https://orcid.org/0000-0003-1675-4037)
- Junli Wu (ORCID: https://orcid.org/0000-0002-4407-0516)
Institutions
- Jiaxing University (CN)
- Changchun University of Chinese Medicine (CN)
- First Hospital of Jiaxing (CN)
Publication Details
- Journal
- Clinical Therapeutics
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1016/j.clinthera.2025.09.009
- Citations
- 1
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.31